...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >HZ08, a great regulator to reverse multidrug resistance via cycle arrest and apoptosis sensitization in MCF-7/ADM.
【24h】

HZ08, a great regulator to reverse multidrug resistance via cycle arrest and apoptosis sensitization in MCF-7/ADM.

机译:HZ08是一种出色的调节剂,可通过MCF-7 / ADM中的周期停滞和细胞凋亡敏化作用来逆转多药耐药性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In early studies, it was demonstrated that R-HZ08, S-HZ08 and the racemate had strong reverse efficacy of multidrug resistance in vitro and in vivo (Yan et al., 2008b). The effect was supposed to have direct interaction with multidrug resistance-associated protein (MRP1) in MCF-7/ADM and P-glycoprotein in K562/A02. According to our latest study, we found HZ08 could enhance chemotherapy induced apoptosis by synergistic action on reactive oxygen species generation, GSH depletion, mitochondrial membrane potential depolarization, cytochrome c release and caspase activation. Moreover, the potential selective effect of HZ08 on resistant cells suggested that HZ08 have specific targets for resistance reversal via apoptosis regulation. Therefore, we traced individual influence of HZ08, not only on apoptosis pathway per se but also on apoptosis related intracellular regulation systems. Then we found HZ08 could increase cells in G(0)/G(1) phase and regulate apoptosis related proteins (Bcl-2, Bax) as well as upstream functional molecules (c-Myc and c-Fos), which are usually abnormal in malignancy and responsible for multidrug resistance in MCF-7/ADM. Thereby, chemotherapy induced apoptosis was promoted. R-HZ08 showed better effect than S-HZ08 or the racemate did in most of targets above. Furthermore, HZ08 did not change the concentration of intracellular Ca(2+) which means it would not have side effect as verapamil does. Considering multidrug resistance is multifactorial, HZ08, especially R-HZ08, which could sensitize apoptosis by multiple improvements of upstream malignant characters, will be a promising drug to enhance the effect of chemotherapy in the treatment of multidrug resistant tumor.
机译:在早期研究中,已证明R-HZ08,S-HZ08和外消旋体在体外和体内都具有很强的逆转多重耐药性的功效(Yan等人,2008b)。推测该作用与MCF-7 / ADM中的多药耐药相关蛋白(MRP1)和K562 / A02中的P-糖蛋白直接相互作用。根据我们的最新研究,我们发现HZ08可以通过对活性氧生成,谷胱甘肽耗竭,线粒体膜电位去极化,细胞色素c释放和胱天蛋白酶激活的协同作用来增强化疗诱导的细胞凋亡。此外,HZ08对耐药细胞的潜在选择性作用表明HZ08具有通过凋亡调控逆转耐药性的特异性靶标。因此,我们追踪了HZ08的个体影响,不仅对细胞凋亡途径本身,而且对与细胞凋亡相关的细胞内调控系统也是如此。然后我们发现HZ08可以增加G(0)/ G(1)期细胞并调节凋亡相关蛋白(Bcl-2,Bax)以及上游功能分子(c-Myc和c-Fos),这些通常是异常的导致恶性肿瘤,并引起MCF-7 / ADM的多药耐药性。因此,促进了化学诱导的细胞凋亡。在以上大多数目标中,R-HZ08表现出比S-HZ08或外消旋体更好的效果。此外,HZ08不会改变细胞内Ca(2+)的浓度,这意味着它不会像维拉帕米那样具有副作用。考虑到多药耐药性是多因素的,HZ08,特别是R-HZ08,可以通过多次改善上游恶性特征来使细胞凋亡敏感,将成为增强化学疗法治疗多药耐药性肿瘤的有前途的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号